[Activity and tolerance of a new anti-arrhythmia drug, Cibenzoline (Cipralan), administered orally)].
The authors studied the effect of a new anti-arrhythmic agent, the Cibenzoline in 9 patients suffering from numerous ventricular extrasystoles (on average 8 extrasystoles/minute). Efficacy was considered to be excellent in 3 cases (complete disappearance of extrasystoles) good in 3 cases (more than 90% decrease in the number of extrasystoles) and poor in 3 cases (these concerned two patients also resistant to all other anti-arrhythmic agents and one patient with an extreme variability of his arrhythmia from one day to another day). Clinical and biological tolerance was excellent. Electrocardiographic parameters in general remained stable, apart from in one case of severe cardiomegaly. The general rules usually accepted for adequate evaluation of the efficacy of an anti-arrhythmic agent are reviewed and discussed.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001835:Body Weight; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D004361:Drug Tolerance; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D007093:Imidazoles; C032151:cifenline
Etude de l'activité et de la tolérance d'un nouvel anti-arythmique, la Cibenzoline (Cipralan), administré par voie orale.